10 results on '"Ricardo Choque-Guevara"'
Search Results
2. Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease
- Author
-
Manolo Fernández Díaz, Katherine Calderón, Aldo Rojas-Neyra, Vikram N. Vakharia, Ricardo Choque-Guevara, Angela Montalvan-Avalos, Astrid Poma-Acevedo, Dora Rios-Matos, Andres Agurto-Arteaga, Maria de Grecia Cauti-Mendoza, Norma Perez-Martinez, Gisela Isasi-Rivas, Luis Tataje-Lavanda, Yacory Sernaque-Aguilar, Freddy Ygnacio, Manuel Criollo-Orozco, Edison Huaccachi-Gonzalez, Elmer Delgado-Ccancce, Doris Villanueva-Pérez, Ricardo Montesinos-Millán, Kristel Gutiérrez-Manchay, Katherinne Pauyac-Antezana, Ingrid Ramirez-Ortiz, Stefany Quiñones-Garcia, Yudith Cauna-Orocollo, Katherine Vallejos-Sánchez, Angela Rios-Angulo, Dennis Núñez-Fernández, Mario I. Salguedo-Bohorquez, Julio Ticona, Manolo Fernández-Sánchez, Eliana Icochea, Luis A. Guevara-Sarmiento, Mirko Zimic, and COVID-19 Working Group in Perú
- Subjects
Medicine ,Science - Abstract
Abstract The coronavirus disease-19 (COVID-19) pandemic has already claimed millions of lives and remains one of the major catastrophes in the recorded history. While mitigation and control strategies provide short term solutions, vaccines play critical roles in long term control of the disease. Recent emergence of potentially vaccine-resistant and novel variants necessitated testing and deployment of novel technologies that are safe, effective, stable, easy to administer, and inexpensive to produce. Here we developed three recombinant Newcastle disease virus (rNDV) vectored vaccines and assessed their immunogenicity, safety, and protective efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters. Intranasal administration of rNDV-based vaccine candidates elicited high levels of neutralizing antibodies. Importantly, the nasally administrated vaccine prevented lung damage, and significantly reduced viral load in the respiratory tract of vaccinated animal which was compounded by profound humoral immune responses. Taken together, the presented NDV-based vaccine candidates fully protected animals against SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial as a promising tool in the fight against COVID-19.
- Published
- 2022
- Full Text
- View/download PDF
3. Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19
- Author
-
Andres Agurto-Arteaga, Astrid Poma-Acevedo, Dora Rios-Matos, Ricardo Choque-Guevara, Ricardo Montesinos-Millán, Ángela Montalván, Gisela Isasi-Rivas, Yudith Cauna-Orocollo, María de Grecia Cauti-Mendoza, Norma Pérez-Martínez, Kristel Gutierrez-Manchay, Ingrid Ramirez-Ortiz, Dennis Núñez-Fernández, Mario I. Salguedo-Bohorquez, Stefany Quiñones-Garcia, Manolo Fernández Díaz, Luis A. Guevara Sarmiento, Mirko Zimic, COVID-19 Working Group in Perú, Ricardo Antiparra, Manuel Ardiles-Reyes, Katherine Calderón, Maria de Grecia Cauti-Mendoza, Naer Chipana-Flores, Xiomara Chunga-Girón, Manuel Criollo-Orozco, Lewis De La Cruz, Nicolás E. Delgado-Pease, Elmer Delgado-Ccancce, Christian Elugo-Guevara, Manolo Fernández-Díaz, Manolo Fernández-Sánchez, Luis Guevara-Sarmiento, Kristel Gutiérrez, Oscar Heredia-Almeyda, Edison Huaccachi-Gonzalez, Pedro Huerta-Roque, Eliana Icochea, Gabriel Jiménez-Avalos, Romina A. Juscamaita-Bartra, Abraham Licla-Inca, Angela Montalván, Adiana Ochoa-Ortiz, Gustavo E. Olivos-Ramirez, Erika Páucar-Montoro, Kathy Pauyac, Jose L. Perez-Martinez, Norma Pérez-M, Daniel Ramos-Sono, Angela A. Rios-Angulo, Aldo Rojas-Neyra, Yomara K. Romero, Yacory Sernaque-Aguilar, Patricia Sheen-Cortavarrı́a, Luis F. Soto, Luis Tataje-Lavanda, Julio Ticona, Katherine Vallejos-Sánchez, A. Paula Vargas-Ruiz, Doris Villanueva-Pérez, Freddy Ygnacio-Aguirre, and Mirko Zimic-Peralta
- Subjects
SARS-CoV-2 ,COVID-19 ,egg-yolk antibodies ,IgY ,passive immunization ,receptor binding domain ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a suitable approach to preclude potential death of infected patients, based on its high specificity/avidity/production yield, cost-effective manufacture, and ease of administration. In the present study, IgY antibodies against a recombinant RBD protein of SARS-CoV-2 were produced in specific-pathogen-free chickens and purified from eggs using a biocompatible method. In vitro immunoreactivity was tested, finding high recognition and neutralization values. Safety was also demonstrated prior to efficacy evaluation, in which body weight, kinematics, and histopathological assessments of hamsters challenged with SARS-CoV-2 were performed, showing a protective effect administering IgY intranasally both as a prophylactic treatment or a post-infection treatment. The results of this study showed that intranasally delivered IgY has the potential to both aid in prevention and in overcoming COVID-19 infection, which should be very useful to control the advance of the current pandemic and the associated mortality.
- Published
- 2022
- Full Text
- View/download PDF
4. Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models
- Author
-
Ricardo Choque-Guevara, Astrid Poma-Acevedo, Ricardo Montesinos-Millán, Dora Rios-Matos, Kristel Gutiérrez-Manchay, Angela Montalvan-Avalos, Stefany Quiñones-Garcia, Maria de Grecia Cauti-Mendoza, Andres Agurto-Arteaga, Ingrid Ramirez-Ortiz, Manuel Criollo-Orozco, Edison Huaccachi-Gonzales, Yomara K. Romero, Norma Perez-Martinez, Gisela Isasi-Rivas, Yacory Sernaque-Aguilar, Doris Villanueva-Pérez, Freddy Ygnacio, Katherine Vallejos-Sánchez, Manolo Fernández-Sánchez, Luis A. Guevara-Sarmiento, Manolo Fernández-Díaz, Mirko Zimic, and for the COVID-19 Working Group in Perú
- Subjects
Medicine ,Science - Abstract
COVID-19 pandemic has accelerated the development of vaccines against its etiologic agent, SARS-CoV-2. However, the emergence of new variants of the virus lead to the generation of new alternatives to improve the current sub-unit vaccines in development. In the present report, the immunogenicity of the Spike RBD of SARS-CoV-2 formulated with an oil-in-water emulsion and a water-in-oil emulsion with squalene was evaluated in mice and hamsters. The RBD protein was expressed in insect cells and purified by chromatography until >95% purity. The protein was shown to have the appropriate folding as determined by ELISA and flow cytometry binding assays to its receptor, as well as by its detection by hamster immune anti-S1 sera under non-reducing conditions. In immunization assays, although the cellular immune response elicited by both adjuvants were similar, the formulation based in water-in-oil emulsion and squalene generated an earlier humoral response as determined by ELISA. Similarly, this formulation was able to stimulate neutralizing antibodies in hamsters. The vaccine candidate was shown to be safe, as demonstrated by the histopathological analysis in lungs, liver and kidney. These results have shown the potential of this formulation vaccine to be evaluated in a challenge against SARS-CoV-2 and determine its ability to confer protection.
- Published
- 2022
5. A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models
- Author
-
Ingrid Ramirez-Ortiz, Manuel Criollo-Orozco, Gisela Isasi-Rivas, Yacory Sernaque-Aguilar, Angela Montalvan, Andres Agurto-Arteaga, Luis Raez Guevara, Norma Perez-Martinez, Mirko Zimic, Maria de Grecia Cauti-Mendoza, Yomara K. Romero Lazaro, Dora Rios-Matos, Edison Huaccachi-Gonzales, Kristel Gutierrez-Manchay, Ricardo Choque-Guevara, Stefany Quinones-Garcia, Manolo Fernández-Díaz, Doris Villanueva-Perez, Ricardo Montesinos-Millan, Katherine Vallejos-Sánchez, Manolo Fernández-Sánchez, and Astrid Poma-Acevedo
- Subjects
Immune system ,biology ,Immunization ,Antigen ,law ,Immunogenicity ,Recombinant DNA ,biology.protein ,Hamster ,Antibody ,Virology ,Virus ,law.invention - Abstract
COVID-19 pandemic has accelerated the development of vaccines against its etiologic agent, SARS-CoV-2. However, the emergence of new variants of the virus requires new immunization strategies in addition to the current vaccines approved for human administration. In the present report, the immunological and safety evaluation in mice and hamsters of a subunit vaccine based on the RBD sub-domain with two adjuvants of oil origin is described.The RBD protein was expressed in insect cells and purified by chromatography until >95% purity. The protein was shown to have the appropriate folding as determined by ELISA and flow cytometry binding assays to its receptor, as well as by its detection by hamster immune anti-S1 sera under non-reducing conditions.In immunization assays in mice and hamsters, the purified RBD formulated with adjuvants based on oil-water emulsifications and squalene was able to stimulate specific neutralizing antibodies and confirm the secretion of IFN-γ after stimulating spleen cells with the purified RBD. The vaccine candidate was shown to be safe, as demonstrated by the histopathological analysis in lungs, liver and kidney. These results demonstrate the potential of the purified RBD administered with adjuvants through an intramuscular route, to be evaluated in a challenge against SARS-CoV-2 and determine its ability to confer protection against infection.
- Published
- 2021
- Full Text
- View/download PDF
6. Preclinical Evaluation of a Newcastle Disease Virus-Vectored Intranasal SARS-CoV-2 Vaccine
- Author
-
Dora Rios-Matos, Astrid Poma-Acevedo, Vikram N. Vakharia, Ricardo Choque-Guevara, Yudith Cauna-Orocollo, Manolo Fernandez Díaz, Stefany Quinones-Garcia, Katherine Vallejos-Sánchez, Dennis Núñez-Fernández, Manolo Fernández-Sánchez, Norma Perez-Martinez, Yacory Sernaque-Aguilar, Elmer Delgado-Ccancce, Katherine Pauyac-Antezana, Mario I. Salguedo-Bohorquez, Andres Agurto Arteaga, Ricardo Montesinos-Millan, Kristel Gutierrez-Manchay, Doris Villanueva-Perez, Luis Guevara-Sarmiento, Ingrid Ramirez-Ortiz, Mirko Zimic, Freddy Ygnacio-Aguirre, Julio Ticona, Manuel Criollo-Orozco, Angela Montalvan, Angela A. Rios-Angulo, Edison Huaccachi-Gonzalez, Maria de Grecia Cauti-Mendoza, Gisela Isasi-Rivas, Katherine Calderón, Luis Tataje-Lavanda, Aldo Rojas-Neyra, and Eliana Icochea
- Subjects
biology ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Nasal administration ,biology.organism_classification ,Newcastle disease ,Virology ,Virus - Abstract
The COVID-19 pandemic has claimed the lives of millions of people. Vaccination is a critical tool for the control of transmission; however, the recent emergence of potentially vaccine-resistant variants renders it important to have a range of vaccines types. It is desirable that vaccines are safe, effective, easy to administer and store, and inexpensive to produce. Newcastle disease virus (NDV), responsible for respiratory disease in chickens, has no pathogenic homologue in humans. We developed two types of NDV-vectored candidate vaccines, and evaluated them in a SARS-CoV-2 challenge in hamsters. Vaccinations resulted in generation of neutralizing antibodies, prevented lung damage, and reduced viral load and viability. In conclusion, our NDV-based vaccine candidate performed well in a SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial. This candidate represents a promising tool in the fight against COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
7. Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease
- Author
-
Manolo Fernández, Díaz, Katherine, Calderón, Aldo, Rojas-Neyra, Vikram N, Vakharia, Ricardo, Choque-Guevara, Angela, Montalvan-Avalos, Astrid, Poma-Acevedo, Dora, Rios-Matos, Andres, Agurto-Arteaga, Maria de Grecia, Cauti-Mendoza, Norma, Perez-Martinez, Gisela, Isasi-Rivas, Luis, Tataje-Lavanda, Yacory, Sernaque-Aguilar, Freddy, Ygnacio, Manuel, Criollo-Orozco, Edison, Huaccachi-Gonzalez, Elmer, Delgado-Ccancce, Doris, Villanueva-Pérez, Ricardo, Montesinos-Millán, Kristel, Gutiérrez-Manchay, Katherinne, Pauyac-Antezana, Ingrid, Ramirez-Ortiz, Stefany, Quiñones-Garcia, Yudith, Cauna-Orocollo, Katherine, Vallejos-Sánchez, Angela, Rios-Angulo, Dennis, Núñez-Fernández, Mario I, Salguedo-Bohorquez, Julio, Ticona, Manolo, Fernández-Sánchez, Eliana, Icochea, Luis A, Guevara-Sarmiento, and Mirko, Zimic
- Subjects
Mice ,Vaccines, Synthetic ,SARS-CoV-2 ,Cricetinae ,Vaccination ,Newcastle disease virus ,Animals ,COVID-19 ,Viral Vaccines ,Antibodies, Viral ,Antibodies, Neutralizing ,Administration, Intranasal - Abstract
The coronavirus disease-19 (COVID-19) pandemic has already claimed millions of lives and remains one of the major catastrophes in the recorded history. While mitigation and control strategies provide short term solutions, vaccines play critical roles in long term control of the disease. Recent emergence of potentially vaccine-resistant and novel variants necessitated testing and deployment of novel technologies that are safe, effective, stable, easy to administer, and inexpensive to produce. Here we developed three recombinant Newcastle disease virus (rNDV) vectored vaccines and assessed their immunogenicity, safety, and protective efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice and hamsters. Intranasal administration of rNDV-based vaccine candidates elicited high levels of neutralizing antibodies. Importantly, the nasally administrated vaccine prevented lung damage, and significantly reduced viral load in the respiratory tract of vaccinated animal which was compounded by profound humoral immune responses. Taken together, the presented NDV-based vaccine candidates fully protected animals against SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial as a promising tool in the fight against COVID-19.
- Published
- 2021
8. Glycoprotein G (gG) production profile during infectious laryngotracheitis virus (ILTV) infection
- Author
-
Ricardo Montesinos, Aldo Rojas-Neyra, Ricardo Choque Guevara, Sandra Morales Ruiz, Katherine Pauyac-Antezana, Jorge Bendezu, and Manolo Fernández-Díaz
- Subjects
0301 basic medicine ,Pulmonology ,Physiology ,Biochemistry ,Virulence factor ,Poultry ,law.invention ,0403 veterinary science ,Herpesvirus 1, Gallid ,Viral Envelope Proteins ,law ,Immune Physiology ,Sf9 Cells ,Medicine and Health Sciences ,Gamefowl ,Enzyme-Linked Immunoassays ,Multidisciplinary ,Immune System Proteins ,Antibodies, Monoclonal ,Eukaryota ,04 agricultural and veterinary sciences ,Herpesviridae Infections ,Recombinant Proteins ,Insects ,embryonic structures ,Vertebrates ,Recombinant DNA ,Medicine ,Biological Cultures ,Antibody ,Baculoviridae ,Research Article ,Arthropoda ,040301 veterinary sciences ,medicine.drug_class ,Science ,Immunology ,Genome, Viral ,Biology ,Spodoptera ,Monoclonal antibody ,Research and Analysis Methods ,Antibodies ,Birds ,03 medical and health sciences ,Immune system ,medicine ,Animals ,Immunoassays ,Inoculation ,Embryonated ,Organisms ,Biology and Life Sciences ,Proteins ,Cell Cultures ,Virology ,Invertebrates ,Monoclonal Antibodies ,030104 developmental biology ,Cell culture ,Fowl ,Amniotes ,Respiratory Infections ,biology.protein ,Immunologic Techniques ,Chickens - Abstract
Glycoprotein G (gG) is a conserved protein, and it has been described as a chemokine-binding protein in most members of the alphaherpesviruses. In case of the infectious laryngotracheitis virus (ILTV), an alphaherpesvirus that infects chickens, this protein is a virulence factor that plays an immunomodulatory role in the chicken immune response. Nevertheless, the gG production profile during ILTV infection has not yet been studied. In this study, we developed monoclonal antibodies in order to determine the gG production profile during ILTV infection in chicken hepatocellular carcinoma (LMH) cell cultures as well as embryonated specific-pathogen-free (SPF) chicken eggs and SPF chickens using a sandwich enzyme-linked immunosorbent assay (ELISA). Despite the fact that inoculated LMH cell cultures showed an increase in both gG production and viral genome copy number up to 96 h after inoculation, we observed that gG production started earlier than the increase in viral genome copy number in ILTV infected embryonated SPF chicken eggs. Likewise, a gG production peak and an increase of viral genome copy number was observed prior to the appearance of clinical signs in infected SPF chickens. According to the production profiles, gG was also produced quite early in eggs and chickens inoculated with ILTV. These findings contribute to the knowledge of the gG role during the ILTV infection as a virulence factor.
- Published
- 2019
9. Development of a lateral flow test for the rapid detection of Avibacterium paragallinarum in chickens suspected of having infectious coryza
- Author
-
Sandra Morales Ruiz, Ricardo Choque Guevara, Ángela Montalván Ávalos, Ricardo Montesinos, Luz Choque Moreau, David Requena, Jorge Bendezu, and Manolo Fernández-Díaz
- Subjects
0301 basic medicine ,Avibacterium paragallinarum ,bird disease ,Haemophilus infection ,Epitope ,law.invention ,0403 veterinary science ,Mice ,Bagg albino mouse ,Limit of Detection ,law ,animal ,Polymerase chain reaction ,Anatis ,Mice, Inbred BALB C ,lcsh:Veterinary medicine ,biology ,Antibodies, Monoclonal ,04 agricultural and veterinary sciences ,General Medicine ,Coinfection ,purl.org/pe-repo/ocde/ford#4.03.00 [https] ,Infectious coryza ,Research Article ,Lateral flow test (LFT) ,Monoclonal antibody ,Haemophilus Infections ,040301 veterinary sciences ,medicine.drug_class ,chicken ,Sensitivity and Specificity ,Rapid detection ,Microbiology ,Lateral flow test ,03 medical and health sciences ,medicine ,Animals ,TonB-dependent transporter (TBDT) ,Poultry Diseases ,mouse ,Haemophilus paragallinarum ,General Veterinary ,microbiology ,biology.organism_classification ,medicine.disease ,veterinary medicine ,030104 developmental biology ,physiology ,lcsh:SF600-1100 ,Chickens ,metabolism - Abstract
Background Infectious coryza (IC) is an acute respiratory disease of growing chickens and layers caused by Avibacterium paragallinarum. The development of tools that allow rapid pathogen detection is necessary in order to avoid disease dissemination and economic losses in poultry. An Av. paragallinarum-specific Ma-4 epitope of the TonB-dependent transporter (TBDT) was selected using bioinformatic tools in order to immunize a BalbC mouse and to produce monoclonal antibodies to be used in a lateral flow test (LFT) developed for Av. paragallinarum detection in chicken nasal mucus samples. Results The 1G7G8 monoclonal antibody was able to detect TBDT in Av. paragallinarum cultures (serogroups: A, B and C) by Western blot and indirect ELISA assay. Consequently, we developed a self-pairing prototype LFT. The limit of detection of the prototype LFT using Av. paragallinarum cultures was 1 × 104 colony-forming units (CFU)/mL. Thirty-five nasal mucus samples from chickens suspected of having infectious coryza were evaluated for the LFT detection capacity and compared with bacterial isolation (B.I) and polymerase chain reaction (PCR). Comparative indicators such as sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive values (NPV) and the kappa index (K) were obtained. The values were 100.0% Se, 50% Sp, 65.4% PPV, 100% NPV, and 0.49 K and 83.9% Se, 100% Sp, 100% PPV, 44.4% NPV, and 0.54 K for the comparison of the LFT with B.I and PCR, respectively. Additionally, the LFT allowed the detection of Av. paragallinarum from coinfection cases of Av. paragallinarum with Gallibacterium anatis. Conclusions The results indicate that the self-pairing prototype LFT is suitable for the detection of TBDT in Av. paragallinarum cultures as well as in field samples such as nasal mucus from Av. paragallinarum-infected chickens. Therefore, this prototype LFT could be considered a rapid and promising tool to be used in farm conditions for Av. paragallinarum diagnosis.
- Published
- 2018
- Full Text
- View/download PDF
10. Glycoprotein G (gG) production profile during infectious laryngotracheitis virus (ILTV) infection.
- Author
-
Jorge Bendezu, Sandra Morales Ruiz, Ricardo Montesinos, Ricardo Choque Guevara, Aldo Rojas-Neyra, Katherine Pauyac-Antezana, and Manolo Fernández-Díaz
- Subjects
Medicine ,Science - Abstract
Glycoprotein G (gG) is a conserved protein, and it has been described as a chemokine-binding protein in most members of the alphaherpesviruses. In case of the infectious laryngotracheitis virus (ILTV), an alphaherpesvirus that infects chickens, this protein is a virulence factor that plays an immunomodulatory role in the chicken immune response. Nevertheless, the gG production profile during ILTV infection has not yet been studied. In this study, we developed monoclonal antibodies in order to determine the gG production profile during ILTV infection in chicken hepatocellular carcinoma (LMH) cell cultures as well as embryonated specific-pathogen-free (SPF) chicken eggs and SPF chickens using a sandwich enzyme-linked immunosorbent assay (ELISA). Despite the fact that inoculated LMH cell cultures showed an increase in both gG production and viral genome copy number up to 96 h after inoculation, we observed that gG production started earlier than the increase in viral genome copy number in ILTV infected embryonated SPF chicken eggs. Likewise, a gG production peak and an increase of viral genome copy number was observed prior to the appearance of clinical signs in infected SPF chickens. According to the production profiles, gG was also produced quite early in eggs and chickens inoculated with ILTV. These findings contribute to the knowledge of the gG role during the ILTV infection as a virulence factor.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.